Summit Therapeutics Plc Stock Alpha and Beta Analysis
| SMMT Stock | USD 19.00 0.58 3.15% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Summit Therapeutics PLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Summit Therapeutics over a specified time horizon. Remember, high Summit Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Summit Therapeutics' market risk premium analysis include:
Beta 2.78 | Alpha 0.55 | Risk 9.61 | Sharpe Ratio 0.0963 | Expected Return 0.93 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Summit |
Summit Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Summit Therapeutics market risk premium is the additional return an investor will receive from holding Summit Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Summit Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Summit Therapeutics' performance over market.| α | 0.55 | β | 2.78 |
Summit Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Summit Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Summit Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Summit Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Summit Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Summit Therapeutics shares will generate the highest return on investment. By understating and applying Summit Therapeutics stock market price indicators, traders can identify Summit Therapeutics position entry and exit signals to maximize returns.
Summit Therapeutics Return and Market Media
The median price of Summit Therapeutics for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 20.03 with a coefficient of variation of 20.25. The daily time series for the period is distributed with a sample standard deviation of 4.02, arithmetic mean of 19.85, and mean deviation of 2.83. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024 | 09/16/2024 |
2 | Acquisition by Mahatme Ujwala of 40500 shares of Summit Therapeutics at 1.67 subject to Rule 16b-3 | 09/20/2024 |
3 | Has Summit Therapeutics Stock Already Peaked | 10/02/2024 |
4 | Acquisition by Clark Kenneth A of 200000 shares of Summit Therapeutics at 19.95 subject to Rule 16b-3 | 10/11/2024 |
5 | Summit Therapeutics Stock Sell or Hold Before Q3 Earnings | 10/24/2024 |
6 | GSK Expands Autoimmune Pipeline with 8.5 Billion Deal for Lupus Drug | 10/29/2024 |
7 | Summit Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Advances and ... | 10/31/2024 |
8 | Why Summit Therapeutics Stock Was a Winner Today | 11/04/2024 |
9 | SMMT Surges as Analyst Initiates Coverage with Buy Rating | 11/05/2024 |
10 | 2 Hot Biopharma Stocks to Buy and Hold for 5 Years | 11/08/2024 |
11 | Merck Inks 3.3B Licensing Deal With Chinese Biotech for Cancer Therapy | 11/15/2024 |
12 | Summit Therapeutics Shares Down 5.9 percent Should You Sell | 11/20/2024 |
13 | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 11/21/2024 |
About Summit Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Summit or other stocks. Alpha measures the amount that position in Summit Therapeutics PLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2020 | 2023 | 2024 (projected) | Payables Turnover | 7.08 | 0.77 | 1.17 | Days Of Inventory On Hand | 43.8K | 39.4K | 41.4K |
Summit Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Summit Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Summit Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Summit Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Summit Therapeutics. Please utilize our Beneish M Score to check the likelihood of Summit Therapeutics' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Summit Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.